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Abstract
Background: One of the most important among risk factors for active tuberculosis development represents diabetes mellitus. The aim of the study was 
the assessment of the predictive factors for pulmonary tuberculosis in Xpert MBT/Rif resistant assay patients with diabetes mellitus.
Material and methods: A retrospective, selective, descriptive and case-control study was performed. Were enrolled 119 pulmonary drug resistant 
tuberculosis patients, diagnosed and hospitalized in the Municipal Clinical Hospital of Phthysiopneumology of Chisinau city in the period of 01.01.2013-
01.01.2015. The patients were distributed in 2 groups: the 1st group – 34 MDR-TB patients with diabetes mellitus and the 2nd – 85 MDR-TB patients. 
Investigations were performed according to the National Clinical Protocol – 123.
Results: The biological characteristics of the pulmonary MDR-TB patients with diabetes mellitus were old age with associated diseases, which contributed 
to a lower treatment outcome. For MDR-TB groups were common social-economic vulnerability, late detection as symptomatic cases and a high treatment 
success rate.
Conclusions: Patients with MDR-TB and diabetes mellitus need an individualized approach for an early TB detection and prompt initiation of the 
adequate treatment regimen according of the susceptibility testing results.
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Introduction
Tuberculosis is one of the most important challenges 
for the health care system and was declared a global emer-
gency in 1993 [45, 46, 47]. In 2017 were registered 9 mil-
lion new cases globally. The Republic of Moldova ranked 
among 30 countries with the biggest burden of multidrug-
resistant tuberculosis (MDR-TB), an estimated disease in-
cidence of 101/100.000 [7]. Health indicators that evalu-
ate the achievement of the sustainable development goals 
associated with tuberculosis are: HIV prevalence, diabetes 
prevalence, alcohol use disorders and tobacco smoking 
prevalence and health expenditure per capita. Diabetes 
mellitus is an important public health problem, one of four 
priority non-communicable diseases targeted by the de-
velopment goals. Diabetes mellitus leads to complications 
and premature death. In the Republic of Moldova every 10th 
citizen suffers from disturbances of glucose metabolism 
and the indices are continuously rising. National capacity 
to prevent and control tuberculosis is reflected by the early 
case detection, especially of MDR-TB cases. The incidence 
of MDR-TB among new and relapsed cases was 19/100.000 
and 64.6/100.000 among retreated cases. Patients with both 
types of diabetes mellitus represent one of the risk groups 
for tuberculosis and should be annually screened by the 
chest X-ray. The association of the diabetes mellitus and 
pulmonary tuberculosis usually occurs in patients where 
diabetes was the previous diagnosed disease [15]. If both, 
tuberculosis and diabetes mellitus are detected simultane-
ously, diabetes worsens the tuberculosis outcome. One half 
of patients with diabetes mellitus develop tuberculosis in 
the first three years after the exposure to the infection [5]. 
Factors associated with the increased risk for tuberculosis 
are: disturbances of the innate resistance, dysfunction of al-
veolar macrophages, low cellular immunity response to the 
specific and non-specific infections, and reduced capacity 
of the organism to produce antibodies, low levels of inter-
feron gamma, microangyopathy (inclusive pulmonary) and 
micronutrient deficiency [35].
The first clinical signs of tuberculosis in patients with 
diabetes mellitus have a low specificity: increased weakness, 
decreased appetite, loss of the weight, and worsening of the 
diabetes symptoms [18]. The development of the chronic 
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forms of tuberculosis – fibro-cavernous type, occurs when 
the organism’s defenses are depleted [29]. The evolution of 
tuberculosis in diabetes mellitus is unfavorable due to dis-
turbances of glucose metabolism [35]. Late detection and 
late onset of the therapy, dietary errors and inadequate 
treatment represent the causes of the worsening of tuber-
culosis process under the specific treatment. In diabetic pa-
tients, blood sugar levels increase, diuresis and glucosuria 
increase, acidosis may appear, patients have the feeling of 
dry mouth, thirst, frequent urination and important weight 
loss [14, 15]. 
Antidiabetic therapy in tuberculosis patients should be 
individualized and depends on the patient’s state, the tu-
berculosis extensibility and the severity of diabetes [27,40]. 
Each patient with diabetes mellitus must be hospitalized. 
First of all, it is necessary to compensate the metabolic dis-
orders with a physiological diet and optimal doses of anti-
diabetic drugs. Anti-tuberculosis therapy should be admin-
istrated with caution due to high rate of adverse reactions 
[39].To prevent possible side effects patients must be strictly 
monitored. 
Although, most of the diabetic patients are misdiag-
nosed regarding tuberculosis, several factors are involved: 
low specificity of the clinical signs and atypical radiological 
aspects. The relevant localization of the pulmonary tubercu-
losis is upper and posterior segments of the lungs: I, II, VI 
and X, while in diabetic patients tuberculosis is identified in 
segments III, IV and V. In patients with carbohydrate me-
tabolism disorders predominate the inferior lobe involve-
ment and may be revealed multiple cavities [18].
According to the WHO recommendation microbiologi-
cal methods remain the golden standard for pulmonary tu-
berculosis diagnosis. Conventional microscopy for identi-
fication of acid-fast-bacilli is the first step in TB detection 
algorithm. The low sensibility of the conventional micros-
copy diminishes the detection efficiency of TB patients. The 
long duration of the culture methods delays TB diagnoses. 
WHO recommends using Xpert MTB/Rif assay in adults, 
children and persons living with HIV or other risk factors. 
Xpert MTB/Rif assay represents in vitro diagnostic medical 
device owned by Cepheid Company. Xpert MTB/Rif assay 
used with Cepheid Xpert MBT/Rif system is a semi-nested, 
quantitative, real-time polymerase chain reaction testing for 
the DNA detection of all Mycobacterium tuberculosis (MBT) 
complex species and rifampicin resistance mutations of the 
rpoB gene [23]. Several standard results must be known 
for appropriate interpretation of Xpert MBT/Rif system: 1. 
MTB detected & RIF resistance means that MTB target is 
present and mutation of rpoBgene is detected; 2. MTB de-
tected & RIF susceptible means that MTB target is present 
and no mutation of rpoB gene has been detected; 3. MTB 
not detected – MTB target is not detected within the sam-
ple. Despite of clearly defined interpretations the test results 
must be always correlated with laboratory and clinical data 
of the investigated patient. Data established that sputum ex-
amination through Xpert MBT/Rif assay shows sensitivity 
among culture positive specimens in an average 97.3% and 
among smear positive patients – 99.5%. The specificity rate 
comparing with non-tuberculosis patients was 97.9% [31]. 
However negative result does not exclude active tuberculo-
sis. 
The aim of the study was the assessment of the predictive 
factors of pulmonary tuberculosis in Xpert MBT/Rif resis-
tant assay patients with diabetes mellitus.
Material and methods
It was performed a retrospective, selective, descriptive 
and case-control study targeting peculiarities of pulmo-
nary MDR-TB patients, diagnosed and hospitalized in the 
Municipal Clinical Hospital of Phthysiopneumology of 
Chisinau city in the period of 01.01.2014-01.01.2016, dis-
tributed in two groups. Including criteria in the 1st group: 
age > 18 years old; patients with pulmonary tuberculo-
sis, established as a new case and diagnosed with diabetes 
mellitus before tuberculosis; positive and resistant Xpert 
MBT/Rif assay; including criteria in the 2nd group: age > 
18 years old; patients with pulmonary tuberculosis estab-
lished as a new case without associated diabetes mellitus; 
positive and resistant Xpert MBT/Rif assay. The total num-
ber of 119 cases was distributed in 2 groups: the 1st group 
(the 1st Group) included 34 patients and the second group 
(the 2nd Group) included 85 patients. Collection of primary 
material involved the extraction of data from medical re-
cord forms. The individual schedule included information 
about: anamnesis, clinical examination, results of radio-
logical investigations (chest radiography, high resolution 
computer tomography), results of microbiological investi-
gations (smear microscopy by Ziehl-Neelson coloration and 
culture on classic solid medium Lowenstein-Jensen or liq-
uid medium). Investigations were performed according to 
the National Clinical Protocol – 123 Tuberculosis in adults. 
Statistical analysis methods used in the study were: compar-
ative, synthesis and discriminant analysis. Mathematic and 
statistical assessment was carried out by checking the quan-
titative and qualitative features. Accumulated material was 
tabled in simple and complex groups. Statistical study was 
performed using Microsoft Excel XP soft. The predictibility 
value of each involved factor was calculated using two by 
two tables. Relative risk and confidence interval was calcu-
lated according to the established formula [7]. The interval 
of 1.2 to 1.6 was assessed as a low predictive factor, 1.6 to 2.4 
– as a mild predictive factor, and more than 2.5 – as a high 
predictive factor.
Results
Assessing general, social and economical peculiarities 
it was established the statistical predominance of male vs 
female in both groups: 21 (61.8%) vs 13 (38.2%) in the 1st 
group and 61 (71.1%) vs 24 (28.3%) in the 2nd group. Com-
paring the groups it was established a moderate predomina-
tion of male in the 2nd group comparing with the 1st group, 
so male/female ratio=1.6/1 in the 1st group and 2.5/1 in the 
2nd group. Assessing the patients according to the age groups 
it was established the statistical predominance of the young 
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patients (18-34 years) in the 2nd group 40 (47.1%) compar-
ing with the 1st group 4 (11.8%) and older than 55 years in 
the 1st group 19 (55.8%) vs 15 (17.6%) in the 2nd group. Sum-
ming patients in two subgroups: under 44 and older than 44 
years, it was identified a statistical difference between the 
predominance of patients less than 44 years in the 2nd group 
52 (61.7%) vs 6 (17.6%) in the 1st group and older than 44 
years in the 1st group 28 (82.3%) vs 25 (29.4%) patients in 
the 2nd group. Considering that old age represents the spe-
cific feature for the group with diabetes and MDR-TB it was 
assessed as a high risk factor for tuberculosis (OR=11,2 95% 
CI: 5.8-60). The data are presented in the table 1.
Table 1
Distribution in sex and age groups
Groups Indices MDR-TB&DM MDR-TB p
n = 34 (P%) n = 85 (P%)
Sex Men 21 (61.8%) 61 (71.1%) >0.05
Women 13 (38.2%) 24 (28.3%) >0.05
18-44 
years
18-24 0 12 (14.1%) <0.05
25-34 4 (11.8%) 28 (33.1%) <0.05
35-44 2 (5.8%) 12 (14.1%) >0.05
>44 
years
45-54 9 (26.5%) 10 (11.8%) >0.05
55-64 12 (35.2%) 12 (14.1%) <0.05
>65 years 7 (20.6%) 3 (3.5%) <0.05
Among patients of both groups a similar distribution 
from rural and urban areas was established, however home-
less were detected only in the 2nd group – 6 (7.1%) patients. 
Distribution of patients by economic groups was relevant. 
Due to the old age of the patients with TB-MDR and DM, 
employed persons statistically predominated in the 1st group 
14 (41.2%) vs 21 (24.%) in the 2nd group. Socially vulnerable 
patients were more frequently registered in the TB-MDR 
group: 52 (61.7%) unemployed patients vs 8 (23%) in the 1st 
group. Low living conditions also predominated in the 2nd 
group 68 (80.1%) vs 21 (61.7%) in the 1st group due to high 
rate of unemployed patients. Retired patients predominated 
in the MDR-TB+DM group: 8 (23.5%) vs 8 (9.4%) in the 1st 
group; the same situation was determined for the persons 
with disabilities: 4 (11.8%) vs 7 (8.3%) patients, respectively 
(tab. 2). 
Table 2
Main demographic, social and economical characteristics
Groups Indices MDR-TB&DM MDR-TB p
n = 34 (P%) n = 85 (P%)
Demo-
graphic 
Urban 17(50.1%) 41 (48.2%) >0.05
Rural 14(41.2%) 38 (44.7) >0.05
Homeless 0 6 (7.1%) >0.05
Economic Employed 14 (41.2%) 21 (24.7%) >0.05
Unemployed 8 (23.5%) 52 (61.7%) <0.01
Retired 8 (23.5%) 8 (9.4%) >0.05
Students 0 5 (5.9%) >0.05
Disease disability 4 (11.8%) 7 (8.3%) >0.05
Life condi-
tions
Low living condi-
tions
21 (61.7%) 68 (80.1%) <0.05
The social risk groups with epidemiological role were 
evaluated. Migrants constituted a similar part in both 
groups, ex-detained were identified only in the MDR-TB 
group (13 (15.3%) cases). Exposure to tuberculosis infection 
(TB contact) statistically predominated in the 1st group – 11 
(52.9%) vs 25 (29.4%) in the 2nd group and was identified as 
a low risk factor (OR=1.1 CI 95% 0.5-2.7). All patients in 
the 1st group and half of the 2nd group had associated dis-
eases. So, the co-morbitities were established as a high risk 
factor (OR=45; CI 95% 42-48) for developing tuberculosis. 
In 15 (44.1%) patients of the 1st group diabetes mellitus was 
diagnosed at the same time as tuberculosis. Regarding the 
harmful habits, active tobacco smoking and alcohol drink-
ing statistically prevailed in the 2nd group. Tobacco smokers 
were 63 (74.1%) in the 1st group vs 13 (39.2%) in the 2nd 
group and alcohol abusers were 38 (44.7%) in the 1st group 
vs 7 (20.6%) cases in the 2nd group (tab. 3).
Table 3
Distribution in risk groups
High risk 
groups
Indices
MDR-
TB&DM
MDR-TB
p
n = 34 (P%) n = 85 (P%)
High risk 
groups
Migrants 6 (17.6%) 16 (18.8%) >0.05
Ex-detained 0 13 (15.3%) <0.05
TB contact 11(52.9%) 25 (29.4%) <0.01
HIV infection 1 (2.9%) 2(2.6%) >0.05
Associated 
diseases
34 (100%) 36 (42.4%) <0.05
Psychiatric disor-
ders
1 (2.9%) 8(9.4%) >0,05
Associated 
harmful 
habits
Tobacco smoking 13 (39.2%) 63 (74.1%) <0.001
Alcohol abusers 7 (20.6%) 38 (44.7%) <0.05
By studing the civil status it was identified a statistical 
higher rate of married patients in the 1st group: 16 (47.1%) 
vs 15 (17.6%) patients in the 2nd group and of the divorced 
and widowed persons: 10 (29.4%) vs 22 (7.1%), respectively. 
Single persons predominated in the 2nd group due to young 
age of most of the patients. When assessing the educational 
level it was established that one half of both groups gradu-
ated general school. The incomplete general educational 
level was more frequently identified in the patients from the 
2nd group: 24 (28.2%) vs 6 (17.6%) in the 1st group. Higher 
education level was established in a limited number of cases 
in both groups. No statistical differences were established 
between the groups of tuberculosis patients (tab. 4).
Table 4
Main social characteristics
Status Indices
MDR-TB&DM MDR-TB
P
n = 34 (P%) n = 85 (P%)
Marital Single 8 (23.5%) 48 (56.5%) <0.01
Married 16 (47.1%) 15 (17.6%) <0.001
Divorced/wi-
dowed
10 (29.4%) 22 (7.1%) <0.05
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Educa-
tion
Primary/illi-
teracy
2 (5.7%) 8 (9.4%) >0.05
Incomplete 
secondary
6 (17.6%) 24 (28.2%) >0.05
General 16 (47.1%) 34 (40.1%) >0.05
Professional 6 (16.6%) 17 (20%) >0.05
Superior 4 (11.7%) 2 (2.4%) >0.05
Studying case-management it was identified that most of 
the patients from the 1st group comparing with the 2nd group 
were detected by high risk group screening, as recommend-
ed by the national protocol: 22 (64.1%) vs 13 (15.3%), re-
spectively. As to symptomatic cases the patients were detect-
ed more often in the 2nd group: 60 (70.6%) vs 12 (35.3%) in 
the 1st group. By direct addressing were detected 12 (14.2%) 
patients in the 2nd group. Microscopic smear positive results 
were established in more than two thirds of patients of both 
groups: 22 (64.1%) in the 1st group and 61 (71.6%) in the 2nd 
group. Positive culture results were 24 (70.6%) patients in 
the 1st group and 76 (89.4%) in the 1st group. Positive results 
of Xpert MTB/Rif assay were more frequently identified in 
patients from the 2nd group: 76 (89.4%) vs 26 (76.5%) in the 
1st group (tab. 5).
Table 5
Case-finding detection, microbiological characteristics 
and treatment outcomes
 Charac-
teristics 
Indices
MDR-
TB&DM
MDR-TB
p
n = 34 (P%) n = 85 (P%)
Case-
finding 
Detected as 
symptomatic 
case
12 (35.3%) 60 (70.6%) <0.001
Detected by ac-
tive screening
22 (64.1%) 13 (15.3%) <0.001
Direct addres-
sing to the 
specialized 
hospital 
0 12 (14.2%) <0.05
Micro-
biological 
positive 
results
Microscopy 22 (64.1%) 61 (71.6%) >0.05
Culture 24 (70.6%) 64 (75.3%) >0.05
Xpert MTB/Rif 26 (76.5%) 76 (89.4%) >0.05
When identifying the radiological characteristics of 
pulmonary tuberculosis patients it was established lung pa-
renchymal destruction in both groups: 25 (73.6%) in the 1st 
group and 61 (71.7%) cases in the 2nd group. Disseminated 
opacities were established at a similar rate in patients of 
both groups: 21 (61.7%) in the 1st group and 58 (68.2%) in 
the 2nd group. Both lungs were affected more frequently in 
patients of the 1st group: 24 (70.6%) vs 49 (57.6%) in the 2nd 
group, but the statistical threshold was not achieved. More 
than three affected segments had 65 (76.5%) patients in the 
2nd group and 22 (64.7%) in the 1st group. Radiologic evo-
lution under the specific treatment with second line anti-
tuberculosis drugs assessed as partial resorption was deter-
mined in a similar proportion in both groups: 28 (82.3%) 
in the 1st group and 76 (89.4%) in the 2nd group. Lung infil-
trates progression was established in higher proportion in 
the 1st group: 7 (20.6%) vs 6 (7.1%) in the 2nd group, which 
contributed to the high rate of died patients. Although in-
filtrative TB form was diagnosed in the majority of patients, 
the severest forms such as disseminated TB and fibro-cav-
ernous TB were diagnosed more frequently in the 1st group: 
6 (17.6%) vs 9 (10.6%) in the 2nd group. Data are exposed in 
the table 6.
Table 6
Case-management characteristics and imagistic features 
 Characte- 
ristics 
Indices
MDR-
TB&DM
MDR-TB
p
n = 34 (P%) n = 85 (P%)
Imagistic Destruction 25 (73.6%) 61 (71.7%) >0.05
Dissemination 21 (61.7%) 58 (68.2%) >0.05
Both lungs 24 (70.6%) 49 (57.6%) >0.05
Extensive TB 22 (64.7%) 65 (76.5%) >0.05
Partial  
resorption
28 (82.3%) 67 (78.8%) >0.05
Progression 7 (20.6%) 6 (7.1%) >0.05
Clinical 
radiological 
forms
Infiltrative 28 (82.3%) 76 (89.4%) >0.05
Disseminated 4 (11.7%) 8 (9.4%) >0.05
Fibro-caver-
nous
2 (5.9%) 1 (1.2%) >0.05
Treatment outcome was assessed using the standardized 
indices. The success rate was lower than recommended by 
WHO (85%) in both groups. The lowest success rate was 
registered in the 1st group: 20 (58.8%) vs the 2nd group 66 
(77.6%). Poor outcomes predominated in the 1st group: 14 
(41.2%) vs the 2nd group 11 (12.9%). The highest rate of died 
patients was identified in the 1st group: 6 (17.5%) comparing 
with the 2nd group 3 (3.5%) (tab. 7).
Table 7
Treatment outcome types
Outcome MDR-TB&DM MDR-TB p
 n = 34 (P%) n = 85 (P%)
Successfully 
treated 
20 (58.8%) 66 (77.6%) <0.05
Died 6 (17.5%) 3 (3.5%) >0.05
Lost to follow-up 5 (14.7%) 8 (9.4%) >0.05
Failure 3 (8.8%) 5 (5.8%) >0.05
Considering all above exposed data it was established 
that the most relevant general and biological characteristics 
of the pulmonary MDR-TB patients associated with dia-
betes mellitus were old age and comorbid state. They were 
more frequently divorced or widowed and were detected by 
active screening according to the national recommenda-
tions (tab. 8).
The most relevant social-economic characteristics of the 
pulmonary MDR-TB patients were economical disadvan-
taged state, low living conditions, single civil state and life 
history of imprisonment. They were more frequently detec-
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Table 8
Odds Ratio assessing factors associated with diabetes 
mellitus and MDR-TB in patients with Xpert MBT/Rif 
resistant results
Factors Odds Ratio
Old age (more than 55) 11.2 (95% CI: 5.8-60), p<0.001
Comorbid state 45 (95% CI: 42-48), p<0.001
Detected by active screening 11.2 (95% CI:11.7-11.4),p<0.05
Divorced or widowed 1. (95% CI: 1.16-1.3), p<0.05
ted as to symptomatic cases and were directly addressedto 
the specialised hospital. Despite the low social-economic 
state and late detection associated with the passive way of 
detection they had a high treatment success, demonstrating 
the strong impact on the disease outcome of the diabetes 
mellitus (tab. 9).
Table 9
Odds Ratio assessing factors associated with MDR-TB in 
patients with Xpert MBT/Rif resistant results
Factors Relative Risk
History of imprisonment 5.6 (95% CI: 5.3-5.9), p<0.05
Economicaly disadvantaged 
state (unemployment)
5.12 (95% CI: 2.9-13.6), p<0.001
Low living conditions 2.5 (95% CI: 1.5-3.8), p<0.001
Single-civil state 3.9 (95% CI: 3.7-4.1), p<0.01
Detected as symptomatic case 4.2 (95% CI: 4.1-4.3), p<0.001
Detected by addressing to the 
specialized hospital
5.3 (95% CI: 4.9-5.7), p<0.05
Successfully treated 1.3 (95% CI: 1.25-1.37), p<0.05
 
Discussion
Association of tuberculosis and diabetes represents an 
epidemiological challenge and important problem for the 
health system in the Republic of Moldova. It was established 
that the tuberculosis prevalence rate among patients with 
diabetes is 1.8–9.5 times higher than in the general popula-
tion [48].
In the Republic of Moldova 12.3% of the population 
have diabetes or reduced tolerance to glucose and 409 pa-
tients died due to diabetic complications in 2015 [7].  Since 
the tuberculosis incidence in the Republic of Moldova 
slowly decreased, the rate of MDR-TB increased.  MDR-TB 
represents another serious threat to the global disease con-
trol. In clinical study was established a strong association 
between the risk factors and MDR-TB. There are several 
risk factors which increase the risk for MDR-TB in patients 
with diabetes: previous treatment, young age, HIV associ-
ated infection, smoking, alcohol and other substances abuse 
[14]. Some clinical studies denoted a high rate (10-23%) 
of MDR-TB among patients with diabetes [15, 20, 40, 42]. 
Other cited factors were: HIV co-infection, age older than 
45, overweight, and male sex [13, 20].
If tuberculosis is detected earlier a more favorable out-
come can be achieved. A severe course of tuberculosis with 
a tendency to the rapid progression and lung parenchyma 
destruction occurs mainly in patients with untreated diabe-
tes mellitus or in late detected tuberculosis [6].
Our study demonstrated a strong influence of diabetes 
on tuberculosis outcome. Obtained results were similar to 
other studies, which determined a high rate of failure and 
death among patients with tuberculosis and diabetes [5, 10, 
24, 29, 38].  Poor treatment outcomes could be explained 
by the co-morbidities such as diabetes, HIV infection, and 
social determinants of health (unemployment, educational 
level, income distribution, social vulnerability, health ser-
vices accessibility) [10]. Nowadays, in the Republic of Mol-
dova the global prevalence of tuberculosis among patients 
with diabetes is high and reflects the general epidemiologi-
cal situation.
Conclusions
 The treatment success rate among patients with drug 
resistant tuberculosis and diabetes was low due to following 
contributing factors: old age and comorbid state. 
More frequently patients with drug resistant tuberculo-
sis and diabetes were detected by active screening and had 
a civil unfavorable state (divorced and widowed), associated 
with old age.
References
1. Alisjahbana B, Sahiratmadja E, Nelwan E J, et al. The effect of type 2 
diabetes mellitus on the presentation and treatment response of pul-
monary tuberculosis. Clinical Infectious Diseases. 2007;45(4):428-35. 
2. Alisjahbana B, van Crevel R, Sahiratmadja E, den Heijer M, Maya A. 
Diabetes mellitus is strongly associated with tuberculosis in Indonesia. 
Int J Tuberc Lung Dis. 2006;10(6):696-700. 
3. Baghaei P, Marjani M, Javanmard P, et al. Diabetes mellitus and tuber-
culosis facts and controversies. J Diabetes Metab Disord. 2013;12(1):58. 
doi: 10.1186/2251-6581-12-58
4. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on 
tuberculosis treatment outcomes: a systematic review.  BMC Medi-
cine. 2011;9:81. doi: 10.1186/1741-7015-9-81. 
5. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, et al. Study of 
fat redistribution and metabolic change in HIV infection (FRAM). J 
Acquir Immune Defic Syndr. 2005;40:119-20. 
6. Beyrer C. HIV epidemiology update and transmission factors: risks 
and risk contexts. 16th International AIDS Conference epidemiology 
plenary. Clin Infect Dis. 2007;44(7):981-7.
7. Centrul National de Management in Sanatate [National Center for 
Health Management]. Indicatori preliminari privind sănătatea po-
pulaţiei şi activitatea instituţiilor medico-sanitare pe anii 2016-2017 
[Preliminary indices on the health of the population and activity of 
the medical sanitary institutions for 2016-2017]. Chisinau: The Center; 
2018, 218 p. Romanian.
8. Chang J-T, Dou H-Y, Yen C-L, et al. Effect of type 2 diabetes mellitus 
on the clinical severity and treatment outcome in patients with pul-
monary tuberculosis: a potential role in the emergence of multidrug-
resistance.  J Formos Med Assoc.  2011;110(6):372-81. doi: 10.1016/
s0929-6646(11)60055-7. 
9. Chao W-C, Yen C-L, Wu Y-H, et al. Increased resisting may suppress 
reactive oxygen species production and inflame some activation in type 
2 diabetic patients with pulmonary tuberculosis infection. Microbes 
Infect. 2015;17(3):195-204. doi: 10.1016/j.micinf.2014.11.009.
10. Pizzol D, Di Gennaro F, Chhaganlal K, et al. Prevalence of diabetes 
mellitus in newly diagnosed pulmonary tuberculosis in Beira, Mo-
zambique. Afr Health Sci. 2017 Sep;17(3):773-9. 
7
8RESEARCH STUDIESThe Moldovan Medical Journal, June 2018, Vol. 61, No 2
11. Diedrich R, O’Hern J, Wilkinson J. HIV-1 and the  M. tuberculo-
sis  granuloma: a systematic review and meta-analysis.  Tuberculo-
sis. 2016;98:62-76. doi: 10.1016/j.tube.2016.02.010.
12. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: con-
vergence of two epidemics. Lancet Infect Dis. 2009;9(12):737-46. doi: 
10.1016/S1473-3099(09)70282-8.
13. Faurholt-Jepsen D, Range N, PrayGod G. The role of anthropometric 
and other predictors for diabetes among urban Tanzanians with tu-
berculosis. Int J Tuberc Lung Dis. 2012;16(12):1680-5. doi: 10.5588/
ijtld.12.0360. 
14. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tu-
berculosis in Europe: a systematic review. Thorax. 2006 Feb;61(2):158-
63. 
15. Garcia F, Solis J, Calderon J, Luque E, Zacarias E. Prevalence of diabetes 
mellitus and related risk factors in an urban population. Revista de la 
Sociedad Peruana de Medicina Interna. 2007;20:90-4.
16. Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S. Tuberculosis 
and nutrition.  Lung India. 2009;26(1):9-16. doi: 10.4103/0970-
2113.45198.
17. Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new 
class of oral antidiabetic drug. Diabetes Obes Metab. 2007;9(2):153-65. 
doi: 10.1111/j.1463-1326.2007.00705.x.
18. Jabbar A, Hussain SF, Khan AA. Clinical characteristics of pulmonary 
tuberculosis in adult Pakistani patients with co-existing diabetes mel-
litus. East Mediterr Health J. 2006;12(5):522-7.
19. Jee SH, Golub JE, Jo J, Park IS, Ohrr H, Samet JM. Smoking and risk 
of tuberculosis incidence, mortality, and recurrence in South Korean 
men and women. Am J Epidemiol. 2009;170(12):1478-85. doi: 10.1093/
aje/kwp308.
20. Kibirige D, Ssekitoleko R, Mutebi E. Overt diabetes mellitus among 
newly diagnosed Ugandan tuberculosis patients: a cross sectional study. 
BMC Infect Dis. 2013;13:122. doi: 10.1186/1471-2334-13-122. 
21. Kumari P, Meena LS. Factors affecting susceptibility to M. tuberculosis: 
a close view of immunological defence mechanism.  Appl Biochem 
Biotechnol. 2014;174(8):2663-73. doi: 10.1007/s12010-014-1217-3.
22. Lachmandas E, van den Heuvel CN, Damen MS, Cleophas MC, et 
al. Diabetes mellitus and increased tuberculosis susceptibility: the 
role of short-chain fatty acids.  J Diabetes Res.  2016;2016:15. doi: 
10.1155/2016/6014631.6014631 
23. Lagman M, Ly J, Saing T, et al. Investigating the causes for decreased 
levels of glutathione in individuals with type II diabetes.  PLoS 
One. 2015;10(3). doi: 10.1371/journal.pone.0118436.e0118436 
24. Leung CC, et al. Lower risk of tuberculosis in obesity. Arch Intern Med. 
2007;167(12):1297-304. doi: 10.1001/archinte.167.12.1297. 
25. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of 
tuberculosis epidemics: the role of risk factors and social determinants. 
Soc Sci Med. 2009;68(12): 2240-6.
26. Lopez N, Gonzalez-Curiel I, Castaneda-Delgado J, et al. Vitamin D 
supplementation promotes macrophages’ anti-mycobacterial activ-
ity in type 2 diabetes mellitus patients with low vitamin D recep-
tor expression.  Microbes Infect.  2014;16(9):755-61. doi: 10.1016/j.
micinf.2014.06.010.
27. Madsbad S. Treatment of type 2 diabetes with incretin-based 
therapies.  Lancet. 2009;373(9662):438-9. doi: 10.1016/S0140-
6736(08)61247-7. 
28. Magee MJ, Kempker RR, Kipiani M, et al. Diabetes mellitus is associ-
ated with cavities, smear grade, and multidrug-resistant tuberculosis 
in Georgia. Int J Tuberc Lung Dis. 2015;19(6):685-92. doi: 10.5588/
ijtld.14.0811. 
29. Mi F, et al. Diabetes mellitus and tuberculosis: pattern of tuberculosis, 
two-month smear conversion and treatment outcomes in Guangzhou, 
China. Trop Med Int Health. 2013;18(11):1379-85. doi: 10.1111/
tmi.12198. 
30. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infec-
tions in patients with type 1 and type 2 diabetes mellitus. Clin Infect 
Dis. 2005;41(3):281-8. doi: 10.1086/431587.
31. Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tu-
berculosis. Pulm Med. 2013;2013:11. doi: 10.1155/2013/828939.828939
32. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is 
strongly reduced in patients with tuberculosis and type 2 diabetes. Clin 
Infect Dis. 2006;43(7):848-54. doi: 10.1086/507543.
33. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, 
Berry MP. The immune response in tuberculosis. Annu Rev Immu-
nol. 2013;31:475-527. 
34. Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E. Control of 
human host immunity to mycobacteria. Tuberculosis. 2005;85(1-2):53-
64. doi: 10.1016/j.tube.2004.09.011. 
35. Baghaei P, Marjani M, Javanmard P, Tabarsi P, Masjedi MR. Diabetes 
mellitus and tuberculosis facts and controversies. J Diabetes Metab 
Disord. 2013;12(1):58.
36. Pathak R, Mishra K, Moonan K, et al. Can intensified tuberculosis case 
finding efforts at nutrition rehabilitation centers lead to pediatric case 
detection in Bihar, India? J Tuberc Res. 2016;4(1):46-54. doi: 10.4236/
jtr.2016.41006. 
37. Liu Q, Li W, Xue M, Chen Y, et al. Diabetes mellitus and the risk of 
multidrug-resistant tuberculosis: a meta-analysis. Sci Rep. 2017;7:1090. 
38. Rasanathan K, Sivasankara Kurup A, Jaramillo E, Lönnroth K. The 
social determinants of health: key to global tuberculosis control. Int J 
Tuberc Lung Dis. 2011 Jun;15 Suppl 2:30-36.
39. Restrepo BI, Schlesinger LS. Host-pathogen interactions in tuber-
culosis patients with type 2 diabetes mellitus. Tuberculosis. 2013;93 
Suppl:S10-4. doi: 10.1016/S1472-9792(13)70004-0.
40. Singh R, Gothi D, Joshi J. Multidrug resistant tuberculosis: role of 
previous treatment with second line therapy on treatment outcome. 
Lung India. 2007;24:54-7. doi: 10.4103/0970-2113.44204.
41. Singla R, Khan N, Al-Sharif N, Ai-Sayegh MO, Shaikh MA, Osman 
MM. Influence of diabetes on manifestations and treatment outcome 
of pulmonary TB patients. Int J Tuberc Lung Dis. 2006;10(1):74-9. 
42. Tanrikulu AC, Hosoglu S, Ozekinci T, Abakay A, Gurkan F. Risk fac-
tors for drug resistant tuberculosis in southeast Turkey. Trop Doct. 
2008;38(2):91-3. doi: 10.1258/td.2007.070131. 
43. Trinh QM, Nguyen HL, Nguyen VN, Nguyen TV, et al. Tuberculosis 
and HIV co-infection-focus on the Asia-Pacific region. Int J Infect Dis. 
2015;32:170-8. doi: 10.1016/j.ijid.2014.11.023. 
44. Webb EA, Hesseling AC, Schaaf HS, et al. High prevalence of Mycobac-
terium tuberculosis infection and disease in children and adolescents 
with type 1 diabetes mellitus. Int J Tuberc Lung Dis. 2009;13(7):868-74. 
45. World Health Organization. Fact sheet on tuberculosis [Internet]. 
Geneva: WHO; 2016 [cited 2017 Oct 16]. Available from:  http://www.
who.int/tb/publications/factsheets/en/
46. World Health Organization. Global tuberculosis report 2016 [Internet]. 
Geneva: WHO; 2016 [cited 2017 Oct 16]. Available from: http://apps.
who.int/medicinedocs/documents/s23098en/s23098en.pdf
47. World Health Organization. Treatment guidelines for drug-resistant 
tuberculosis, 2016 update [Internet]. Geneva: WHO; 2016 [cited 2017 
Oct 16]. Available from: http://www.who.int/tb/areas-of-work/drug-
resistant-tb/treatment/resources/en/ 
48. Zheng C, Hu M, Gao F. Diabetes and pulmonary tuberculosis: a 
global overview with special focus on the situation in Asian countries 
with high TB-DM burden. Glob Health Action. 2017;10(1):1-11. doi: 
10.1080/16549716.2016.1264702.
49. Zozulinska D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-
Wysocka B. Serum interleukin-8 level is increased in diabetic pa-
tients. Diabetologia. 1999;42(1):117-8. doi: 10.1007/s001250051124.
